• Ralph Lauren Tempus Ai Tem Stock Forecast

$283.000 value
$163.00 (15% off)VIPapplied$283.000

Fundamental analysis positions TEM as a growth leader in AI healthcare, with revenue expansion expected to drive the stock toward $44.80 over the next three earnings cycles based on forecast models. “Molecular profiling tests are increasingly a critical part of patients’ treatment journeys as they enable physicians to make more informed decisions on a deeply personalized level. In addition to offering one of the most comprehensive testing portfolios, our mission is to expand access to the many patients in need of optimized care”. Last week, the company received FDA 510(k) clearance for the Tempus xR IVD device , designed for tumor analysis. This diagnostic tool helps drugmakers identify patients most likely to respond to cancer treatments, making clinical trials more efficient by focusing on those with the highest chance of positive outcomes. The FDA clearance could create new commercial opportunities for Tempus through partnerships with biopharma companies. Wall Street consensus on Tempus AI TEM stock forecast sits at “Buy,” supported by forward P/E of 28.4, competitive in the AI healthcare sector. Growth momentum remains aligned with broader Nasdaq healthtech trends.

Arrives by Thu. Oct. 9

Eligible for Same-Day Delivery. Order by 12pm.
  • 8
  • 4
  • 3
  • 11
  • 8

Offers & perks

loyallist icon
Join Star Rewards & get free shipping at $39
Exclusions
Not a Star Rewards member? Get free shipping at $49
Exclusions apply